11 completed, 3 unknown, 2 recruiting. 8 Phase 2, 5 Phase 1, 5 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 2, Unknown 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 4 | 2 | Unknown 2 |
Follow Allopurinol 300 MG: new trials by email Literature Review of Allopurinol 300 MG trials Research Report on Allopurinol 300 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allopurinol in Depression Sertraline 50 MG, Allopurinol 300 MG - Depression | Phase 2 / Phase 3 | Recruiting | Tanta University | 70 | 2026-05-20 | 2026-08-18 |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis Allopurinol 300 MG, Atorvastatin 20mg, Placebo - Cirrhosis, Hepatic Encephalopathy | Phase 2 / Phase 3 | Completed | Tanta University | 150 | 2022-11-15 | 2026-08-11 |
| Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients Trimetazidine 35 mg, Allopurinol 300 MG, Normal saline - AKI - Acute Kidney Injury | Phase 4 | Unknown | Beni-Suef University | 124 | 2022-09-19 | 2023-01-19 |
| Allopurinol to Prevent Cirrhosis Related Morbidities Placebo, Allopurinol 300 MG - Cirrhosis | Phase 2 / Phase 3 | Completed | Tanta University | 100 | 2022-06-15 | 2023-05-09 |
| Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms Allopurinol 300 MG, Placebo oral tablet - Refractory Angina | Phase 2 / Phase 3 | Unknown | Ministry of Health, Brazil | 40 | 2021-03-03 | 2021-02-24 |
| A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart Verinurad, Placebo, Allopurinol - Healthy Volunteers (Intended Indication: Chronic Kidney Disease) | Phase 1 | Completed | AstraZeneca | 24 | 2020-03-03 | 2022-01-31 |
| A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout SHR4640 dose1, SHR4640 dose2, Placebo oral tablet - Gout | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 594 | 2019-07-16 | 2022-06-13 |
| Lowering Uric Acid in Live Kidney Donors Allopurinol 300 mg, Placebo Oral Tablet - Renal Transplant Donor of Left Kidney, Renal Transplant Donor of Right Kidney | Phase 2 | Completed | Oslo University Hospital | 71 | 2018-01-17 | 2021-02-24 |
| Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence. lesinurad/allopurinol 200/300 FDC tablets, lesinurad 200 mg, allopurinol 300 mg - Gout | Phase 1 | Completed | Ardea Biosciences, Inc. | 32 | 2017-08-14 | 2018-11-07 |
| Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Atorvastatin 80mg, ALLOPURINOL 300 MG, Atorvastatin 80mg AND allopurinol 300 mg - Diabetes Mellitus Type 2 Platelets Reactivity Statin | Phase 4 | Unknown | University of Roma La Sapienza | 200 | 2017-03-28 | 2017-06-22 |
| Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence lesinurad/allopurinol 200/300 FDC tablet, lesinurad 200 mg, allopurinol 300 mg - Healthy | Phase 1 | Completed | Ardea Biosciences, Inc. | 28 | 2016-08-30 | 2017-06-16 |
| Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability lesinurad/allopurinol 200/300 FDC tablets, lesinurad 200 mg, allopurinol 300 mg - Healthy | Phase 1 | Completed | Ardea Biosciences, Inc. | 116 | 2015-10-01 | 2016-12-19 |
| Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects RDEA3170 2.5 mg, allopurinol 300 mg - Gout | Phase 2 | Completed | Ardea Biosciences, Inc. | 41 | 2015-07-28 | 2018-01-23 |
| RDEA3170 and Allopurinol Combination Study in Gout Subjects RDEA3170 10 mg, allopurinol 300 mg - Gout | Phase 1 | Completed | Ardea Biosciences, Inc. | 12 | 2014-11-01 | 2017-12-20 |
| Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg - Gout | Phase 2 | Completed | Gilead Sciences | 248 | 2014-03-01 | 2018-01-29 |
Gout (5) · Fibrosis (2) · Acute Kidney Injury (1) · Angina Pectoris (1) · Ascites (1) · Burkitt Lymphoma (1) · Coronary Artery Disease (1) · Depression (1) · Hepatic Encephalopathy (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Plasma Cell (1)
Ardea Biosciences, Inc. (5) · Tanta University (3) · AstraZeneca (1) · Beni-Suef University (1) · Gilead Sciences (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Masonic Cancer Center, University of Minnesota (1) · Ministry of Health, Brazil (1) · Oslo University Hospital (1) · University of Roma La Sapienza (1)
United States (6) · Egypt (4) · Brazil (2) · Canada (1) · China (1) · Georgia (1) · Germany (1) · Italy (1) · Norway (1)
N. Bhakta (3) · Chunde Bao (1) · Dag Olav Dahle, MD, PhD (1) · Hadeer Safwat Hassan Zaki, Doctor (1) · Hatem Hossam Mowafi, Doctor (1) · J. Hall, MD (1) · Jesse Hall, MD (1) · Luis Henrique W Gowdak, MD, PhD (1) · Mark Juckett (1) · Naglaa Samir Bazan, Assoc. Prof (1) · Nourhan Osama Ali Moselhy, BSc (1)
PMID 26989892, PMID 29531784, PMID 36504291, PMID 37832758
2017 (1), 2018 (1)